CTOR CITIUS ONCOLOGY, INC.
Price Chart
Executive Summary
Citius Oncology reported fiscal Q2 2026 (March 31, 2026) net product revenue of $1.7M, down from $3.9M in Q1 due to initial channel fill normalization, with 80% gross margins. The company secured up to $36.5M in post-quarter debt/equity financing (including $10M term loan funded and ~$11.5M warrant exercises) but posted a net loss of $26.6M driven by a $19.7M one-time CMO contract cancellation charge. Cash stood at $2.6M pre-financing, with runway extended only through November 2026, and Jefferies retained to evaluate strategic alternatives.
Key Financial Metrics
Actionable Insight
The Q2 revenue decline from $3.9M to $1.7M reflects expected channel fill normalization, but the $19.7M CMO cancellation charge and $2.6M pre-financing cash position highlight severe capital constraints. The post-quarter $36.5M financing and Jefferies strategic review suggest a potential sale or partnership is being actively explored. Watch for updates on new BDS supplier agreements and formulary conversion rates as key leading indicators of commercial traction.
Key Facts
- Q2 FY2026 net product revenue of $1.7M (vs $0 in prior-year period); Q1 was $3.9M reflecting initial distributor channel fill
- Gross margin of 80% on product revenue; $4.5M gross profit on $5.6M H1 revenue
- Net loss of $26.6M for Q2, vs $7.7M in prior-year period, driven by $19.7M one-time CMO contract cancellation charge
- Cash and cash equivalents of $2.6M as of March 31, 2026, before post-quarter financings
- Secured up to $36.5M post-quarter: $10M funded term loan from Avenue Capital (up to $25M total) and ~$11.5M from warrant exercises
- 83% of target accounts on formulary or in review; near 100% payer coverage with no reimbursement denials
- Retained Jefferies LLC as exclusive financial advisor to evaluate strategic alternatives
- Expects combined Citius Oncology and Citius Pharma funds to sustain operations only through November 2026
- Initiated first European shipment via Named Patient Programs across 19 markets
- Positive topline Phase 1 combo data for LYMPHIR with pembrolizumab and pre-CAR-T in DLBCL
Financial Impact
Q2 revenue $1.7M (down 56% QoQ from $3.9M in Q1 due to channel fill normalization); net loss $26.6M including $19.7M one-time charge; post-quarter financing of up to $36.5M provides runway only through Nov 2026
Risk Factors
- Cash runway only through November 2026 even after $36.5M financing — substantial additional capital needed
- Q2 revenue decline from Q1 suggests slower-than-expected demand conversion from channel fill to treatment-driven reorders
- $19.7M CMO cancellation charge signals supply chain disruption risk during commercial ramp
- Dilution from warrant exercises and potential future equity raises; shares outstanding increased from 83.5M to 93.0M since September 2025
- Nasdaq continued listing compliance risk flagged in forward-looking statements
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-057883 |
| Document: ea0291035-8k_citius.htm | 0001213900-26-057883 |
| Document: 0001213900-26-057883-index-headers.html | 0001213900-26-057883 |
| Document: 0001213900-26-057883-index.html | 0001213900-26-057883 |
| Document: 0001213900-26-057883.txt | 0001213900-26-057883 |
| 8-K Data (Synthetic) | 0001213900-26-057883 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
2d ago
|
EFFECT
| $0.7786 awaiting T+1 | awaiting T+1 | — | $0.8000 (−2.75%) |
|
Jun 1, 2026
8d ago
|
8-K
| $0.7830 $0.7800 | ▼ −0.38% | ▲ +0.34% | $0.8000 (+2.17%) |
|
May 29, 2026
11d ago
|
S-3
| $0.7920 $0.7830 | ▲ +1.14% | ▲ +1.28% | $0.8000 (−1.01%) |
|
May 15, 2026
25d ago
|
8-K
| $0.8290 $0.8280 | ▼ −0.12% | ▲ +0.53% | $0.8000 (−3.50%) |
|
Mar 3, 2026
14w ago
|
EFFECT
| $1.06 $1.09 | ▲ +2.83% | ▲ +2.07% | $0.8000 (−24.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access